Literature DB >> 27322972

Myocardial Extracellular Volume Fraction with Dual-Energy Equilibrium Contrast-enhanced Cardiac CT in Nonischemic Cardiomyopathy: A Prospective Comparison with Cardiac MR Imaging.

Hye-Jeong Lee1, Dong Jin Im1, Jong-Chan Youn1, Suyon Chang1, Young Joo Suh1, Yoo Jin Hong1, Young Jin Kim1, Jin Hur1, Byoung Wook Choi1.   

Abstract

Purpose To evaluate the feasibility of equilibrium contrast material-enhanced dual-energy cardiac computed tomography (CT) to determine extracellular volume fraction (ECV) in nonischemic cardiomyopathy (CMP) compared with magnetic resonance (MR) imaging. Materials and Methods This study was approved by the institutional review board; informed consent was obtained. Seven healthy subjects and 23 patients (six with hypertrophic CMP, nine with dilated CMP, four with amyloidosis, and four with sarcoidosis) (mean age ± standard deviation, 57.33 years ± 14.82; 19 male participants [63.3%]) were prospectively enrolled. Twelve minutes after contrast material injection (1.8 mL/kg at 3 mL/sec), dual-energy cardiac CT was performed. ECV was measured by two observers independently. Hematocrit levels were compared between healthy subjects and patients with the Mann-Whitney U test. In per-subject analysis, interobserver agreement for CT was assessed with the intraclass correlation coefficient (ICC), and intertest agreement between MR imaging and CT was assessed with Bland-Altman analysis. In per-segment analysis, Student t tests in the linear mixed model were used to compare ECV on CT images between healthy subjects and patients. Results Hematocrit level was 43.44% ± 1.80 for healthy subjects and 41.23% ± 5.61 for patients with MR imaging (P = .16) and 43.50% ± 1.92 for healthy subjects and 41.35% ± 5.92 for patients with CT (P = .15). For observer 1 in per-subject analysis, ECV was 34.18% ± 8.98 for MR imaging and 34.48% ± 8.97 for CT. For observer 2, myocardial ECV was 34.42% ± 9.03 for MR imaging and 33.98% ± 9.05 for CT. Interobserver agreement for ECV at CT was excellent (ICC = 0.987). Bland-Altman analysis between MR imaging and CT showed a small bias (-0.06%), with 95% limits of agreement of -1.19 and 1.79. Compared with healthy subjects, patients with hypertrophic CMP, dilated CMP, amyloidosis, and sarcoidosis had significantly higher myocardial ECV at dual-energy equilibrium contrast-enhanced cardiac CT (all P < .01) in per-segment analysis. Conclusion Myocardial ECV with dual-energy equilibrium contrast-enhanced CT showed good agreement with MR imaging findings, suggesting the potential of myocardial tissue characterization with CT. (©) RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27322972     DOI: 10.1148/radiol.2016151289

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  32 in total

1.  Point estimate and reference normality interval of MRI-derived myocardial extracellular volume in healthy subjects: a systematic review and meta-analysis.

Authors:  Francesco Sardanelli; Simone Schiaffino; Moreno Zanardo; Francesco Secchi; Paola Maria Cannaò; Federico Ambrogi; Giovanni Di Leo
Journal:  Eur Radiol       Date:  2019-05-02       Impact factor: 5.315

2.  Myocardial extracellular volume quantification in cardiac CT: comparison of the effects of two different iterative reconstruction algorithms with MRI as a reference standard.

Authors:  Takafumi Emoto; Masafumi Kidoh; Seitaro Oda; Takeshi Nakaura; Yasunori Nagayama; Akira Sasao; Yoshinori Funama; Satoshi Araki; Seiji Takashio; Kenji Sakamoto; Eiichiro Yamamoto; Koichi Kaikita; Kenichi Tsujita; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2019-08-30       Impact factor: 5.315

3.  Dual-contrast agent photon-counting computed tomography of the heart: initial experience.

Authors:  Rolf Symons; Tyler E Cork; Manu N Lakshmanan; Robert Evers; Cynthia Davies-Venn; Kelly A Rice; Marvin L Thomas; Chia-Ying Liu; Steffen Kappler; Stefan Ulzheimer; Veit Sandfort; David A Bluemke; Amir Pourmorteza
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-13       Impact factor: 2.357

Review 4.  Computed tomography of cardiomyopathies.

Authors:  Kevin Kalisz; Prabhakar Rajiah
Journal:  Cardiovasc Diagn Ther       Date:  2017-10

5.  Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma.

Authors:  Yoshihiko Fukukura; Yuichi Kumagae; Ryutaro Higashi; Hiroto Hakamada; Masatoyo Nakajo; Kosei Maemura; Shiho Arima; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

Review 6.  Multimodality imaging assessment of mitral valve anatomy in planning for mitral valve repair in secondary mitral regurgitation.

Authors:  Romain Capoulade; Nicolas Piriou; Jean-Michel Serfaty; Thierry Le Tourneau
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 7.  Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedside.

Authors:  Gaston A Rodriguez-Granillo
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

8.  Myocardial Late Iodine Enhancement and Extracellular Volume Quantification with Dual-Layer Spectral Detector Dual-Energy Cardiac CT.

Authors:  Seitaro Oda; Takafumi Emoto; Takeshi Nakaura; Masafumi Kidoh; Daisuke Utsunomiya; Yoshinori Funama; Yasunori Nagayama; Seiji Takashio; Mitsuharu Ueda; Taro Yamashita; Kenichi Tsujita; Yukio Ando; Yasuyuki Yamashita
Journal:  Radiol Cardiothorac Imaging       Date:  2019-04-25

Review 9.  Cardiac Computed Tomography - More Than Coronary Arteries? A Clinical Update.

Authors:  Jana Taron; Borek Foldyna; Parastou Eslami; Udo Hoffmann; Konstantin Nikolaou; Fabian Bamberg
Journal:  Rofo       Date:  2019-06-27

10.  Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study.

Authors:  Virgile Chevance; Thibaud Damy; Vania Tacher; François Legou; Fourat Ridouani; Alain Luciani; Hicham Kobeiter; Alain Rahmouni; Jean-François Deux
Journal:  Eur Radiol       Date:  2017-08-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.